Aprepitant Triple Therapy for the Prevention of CINV in Nondrinking and Young Women Who Received Moderately Emetogenic Chemotherapy

Inclusion Criteria: * Diagnosed by pathology as gastrointestinal carcinoma and no previous FOLFOX or FOLFIRI based regimen chemotherapy history. * Female. * Adult patients ( ≥ 18, ≤ 50 years of age) * No long-term or excessive alcohol intake history:1.Alcohol intake less than 5 times per week; 2.Alcohol intake less than 100g per day. * Performance status ECOG 0-1 * Adequate haematological, hepatic, renal and metabolic function parameters: Leukocytes : 3,500-10,000/mm3, ANC ≥ 1,500/mm3, Platelets ≥ 90,000/mm3, Hb \> 9g/dl (may be transfused or treated with erythropoietin to maintain or exceed this level), Serum creatinine ≤ 1 x upper limit of normal, Bilirubin ≤ 1.5 x upper limit of normal, Serum AST, ALT, ALP ≤ 2.5 x upper limit of normal in absence of liver metastases, or ≤ 5 x upper limit of normal in presence of liver metastases. * Negative pregnancy test. If pregnancy test were positive, subject should be included in the trial only when the subsequent pregnancy test is negative. * Ability of reading, comprehending and finishing trial questionnaires and record, including VAS (Visual Analogue Scale) question. * Before subject registration, written informed consent must be given according to local regulations. Exclusion Criteria: * Pregnant women without morning sickness. * Presence of gastrointestinal tract obstruction or electrolyte imbalance. * Any history of central nervous system disease(e.g. Primary brain tumour, seizure not controlled with standard medical therapy, brain metastases or history of stroke). * Contraindication of glucocorticoid:1.Infection of virus, bacteria or fungus uncontrolled by antibiotics; 2.Active stomach or duodenum ulcer; 3.Severe hypertension, atherosclerosis, diabetes; 4.Osteoporosis;5.Corneal ulcer; 6.Pregnancy; 7.Reparative phase of trauma, operation or fraction; 8.Hypercortisolism; 9.Severe mental disorder or epilepsy; 10.Inadequate cardiac or renal function. * Mental disability or severe emotional or mental disorder. * Active infection(e.g. pneumonia, hepatitis) or any uncontrolled disease(e.g.diabetic ketoacidosis) that may affect study outcome or expose patients to unnecessary risk. * Usage of any illicit drug, including medical marijuana or alcohol abusing(China drug dependence criteria). * Treatment of unapproved medicine in the previous 4 weeks. * Concomitant therapy of psychotropic medicine such as olanzapine. * Hypersensitivity history towards Aprepitant, 5-HT3 receptor antagonist or dexamethasone. * Previous treatment of Aprepitant. * Unable to swallow capsules. * Main researchers considered that the patient is unsuited to the trial. * Unable or unwilling to follow research programme.